NO20051187L - Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon - Google Patents

Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon

Info

Publication number
NO20051187L
NO20051187L NO20051187A NO20051187A NO20051187L NO 20051187 L NO20051187 L NO 20051187L NO 20051187 A NO20051187 A NO 20051187A NO 20051187 A NO20051187 A NO 20051187A NO 20051187 L NO20051187 L NO 20051187L
Authority
NO
Norway
Prior art keywords
depositional
suspension
active
formulations consisting
arylheterocyclic
Prior art date
Application number
NO20051187A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20051187L publication Critical patent/NO20051187L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmasøytisk sett for fremstilling av en injiserbar depotformulering av en aryl-heterocyklisk farmasøytiske forbindelse, så som ziprasidon og en metode for fremstilling av nevnte depotformulering er beskrevet.
NO20051187A 2002-10-25 2005-03-04 Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon NO20051187L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42129502P 2002-10-25 2002-10-25
PCT/IB2003/004535 WO2004037224A1 (en) 2002-10-25 2003-10-13 Depot formulations of arylheterocyclic active agents in the form of a suspension

Publications (1)

Publication Number Publication Date
NO20051187L true NO20051187L (no) 2005-04-11

Family

ID=32176696

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051187A NO20051187L (no) 2002-10-25 2005-03-04 Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon

Country Status (21)

Country Link
US (1) US20040146562A1 (no)
EP (1) EP1562546A1 (no)
JP (2) JP2006505579A (no)
KR (1) KR20050071611A (no)
CN (1) CN1703198A (no)
AR (1) AR041826A1 (no)
AU (1) AU2003267763A1 (no)
BR (1) BR0315663A (no)
CA (1) CA2498276A1 (no)
GT (1) GT200300227A (no)
MX (1) MXPA05004299A (no)
NL (1) NL1024616C (no)
NO (1) NO20051187L (no)
PA (1) PA8586301A1 (no)
PE (1) PE20040471A1 (no)
PL (1) PL375603A1 (no)
RU (1) RU2292207C2 (no)
TW (1) TW200418477A (no)
UY (1) UY28035A1 (no)
WO (1) WO2004037224A1 (no)
ZA (1) ZA200501979B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE428423T1 (de) 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
DK2218448T3 (en) 2002-12-13 2016-01-11 Durect Corp An oral drug delivery system comprising liquid carrier materials of high viscosity
JP2007522095A (ja) * 2003-05-16 2007-08-09 ファイザー・プロダクツ・インク ジプラシドンを用いた不安の治療
WO2006000913A1 (en) * 2004-06-23 2006-01-05 Pfizer Products Inc. Method for sterile filtration of viscous pharmaceutical compositions
BRPI0515372B8 (pt) 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
WO2006096462A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
AU2007248949B2 (en) * 2006-05-09 2010-04-08 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
WO2008066642A2 (en) 2006-11-03 2008-06-05 Durect Corporation Transdermal delivery systems comprising bupivacaine
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN109803654B (zh) 2017-02-23 2022-06-28 上海华汇拓医药科技有限公司 一种多奈哌齐半帕莫酸盐的粉针剂、包含其的组合物及它们的制备方法
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002265A1 (en) * 1987-09-07 1989-03-23 Teijin Limited Medicine-containing fat emulsion of the type prepared immediately before use and process for preparing medicine-containing fat emulsion
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
ATE277641T1 (de) * 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
CA2275525C (en) * 1996-12-20 2011-02-08 Kevin J. Brodbeck Gel composition and methods
ES2294814T3 (es) * 1997-05-16 2008-04-01 Amgen Inc. Geles de liberacion retardada y sostenida.
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EP1181018B1 (en) * 1999-05-27 2003-03-12 Pfizer Products Inc. Ziprasidone suspension
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
US20030055023A1 (en) * 2001-03-20 2003-03-20 Rajewski Roger A. Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2458968A1 (en) * 2001-08-31 2003-03-13 The Rockefeller University Method for classification of anti-psychotic drugs

Also Published As

Publication number Publication date
RU2005112202A (ru) 2005-11-20
GT200300227A (es) 2004-06-23
BR0315663A (pt) 2005-08-30
KR20050071611A (ko) 2005-07-07
CA2498276A1 (en) 2004-05-06
US20040146562A1 (en) 2004-07-29
RU2292207C2 (ru) 2007-01-27
PA8586301A1 (es) 2004-05-07
CN1703198A (zh) 2005-11-30
UY28035A1 (es) 2004-05-31
PE20040471A1 (es) 2004-08-14
NL1024616A1 (nl) 2004-04-27
AR041826A1 (es) 2005-06-01
NL1024616C (nl) 2010-04-19
WO2004037224A1 (en) 2004-05-06
PL375603A1 (en) 2005-12-12
ZA200501979B (en) 2006-04-26
JP2006505579A (ja) 2006-02-16
JP2006219501A (ja) 2006-08-24
EP1562546A1 (en) 2005-08-17
MXPA05004299A (es) 2005-08-03
AU2003267763A1 (en) 2004-05-13
TW200418477A (en) 2004-10-01

Similar Documents

Publication Publication Date Title
NO20051187L (no) Depotformuleringer bestaende av aktive arylheterocykliske forbindelser i form av en suspensjon
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MXPA06012595A (es) Analogos de amino-tetrazoles y metodos de uso.
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
NO20066055L (no) Pyridinderivater
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BR0308452A (pt) composições farmacêuticas e métodos de preparação de composição farmacêutica
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
DK1268471T3 (da) N-heterocykliske derivater som NOS-inhibitorer
WO2004014388A8 (en) 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
NO20054787D0 (no) Indenderivater som farmasotiske midler
ATE484508T1 (de) Furylverbindungen
NO20050666L (no) 2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
WO2004093800A3 (en) Thyronamine derivatives and analogs and methods of use thereof
AU2003250471A1 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20063293L (no) Farmasoytiske forbindelser
IL173809A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application